key: cord-0928292-3m2y2q89 authors: Theoharides, Theoharis C.; Cholevas, Christos; Polyzoidis, Konstantinos; Politis, Antonios title: Long‐COVID syndrome‐associated brain fog and chemofog: Luteolin to the rescue date: 2021-04-12 journal: Biofactors DOI: 10.1002/biof.1726 sha: 1b16940093e44209acb31acab44432d22d4f4837 doc_id: 928292 cord_uid: 3m2y2q89 COVID‐19 leads to severe respiratory problems, but also to long‐COVID syndrome associated primarily with cognitive dysfunction and fatigue. Long‐COVID syndrome symptoms, especially brain fog, are similar to those experienced by patients undertaking or following chemotherapy for cancer (chemofog or chemobrain), as well in patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) or mast cell activation syndrome (MCAS). The pathogenesis of brain fog in these illnesses is presently unknown but may involve neuroinflammation via mast cells stimulated by pathogenic and stress stimuli to release mediators that activate microglia and lead to inflammation in the hypothalamus. These processes could be mitigated by phytosomal formulation (in olive pomace oil) of the natural flavonoid luteolin. Infection with the recent coronavirus (severe acute respiratory syndrome [SARS]-CoV-2) leads to COVID-19, the severity of which derives from the host's inflammatory response that involves release of a storm of proinflammatory cytokines, 1-7 especially interleukin-6 (IL-6), [8] [9] [10] [11] but also IL-1. 12, 13 Even though symptoms associated with SARS-CoV-2 infection in children are mild, a number of recent publications reported a multisystem inflammatory syndrome (MIA-C) in older children [14] [15] [16] and adolescents, 17 often presenting with symptoms reminiscent of Kawasaki disease. 16 Symptoms in MIA-C typically occur 4-6 weeks after infection and the disease is characterized by elevated markers of inflammation 18 and the presence of multiple autoantibodies. 18 A similar disease in adults, Abbreviations: AD, Alzheimer's disease; ACE2, angiotensin converting enzyme 2; BBB, blood-brain barrier; CNS, central nervous system; CRH, corticotropin-releasing hormone; DAMPs, damage-associated molecular patterns; HPA, hypothalamic-pituitary-adrenal; MCAS, mast cell activation syndrome; MCI, mild cognitive impairment; mtDNA, mitochondrial DNA; ME/CFS, myalgic encephalomyelitis/chronic fatigue syndrome; PAMPs, pathogen-associated molecular patterns; PAF, platelet activating factor; SP, substance P; SM, systemic mastocytosis; TLCOVID-19, toll-like receptor. named multisystem inflammatory syndrome (MIA-A) has been recognized by the Center for Disease Control (CDC, USA) (https://www.cdc.gov/mis-c/). In fact, autoimmune and inflammatory diseases are now increasingly identified following COVID-19. 19 The etiology of MIA remains unknown. Cytokine storms have also been implicated in a variety of "mystery" diseases. 20 One such disease affects COVID-19 survivors and is associated with severe fatigue and neuropsychiatric symptoms (https://www. health.harvard.edu/blog/the-tragedy-of-the-post-covidlong-haulers-2020101521173), especially impairment in cognitive functions known as "brain fog" (https://www. nytimes.com/2020/10/11/health/covid-survivors.html). Such patients have been called "long-haulers" (https:// directorsblog.nih.gov/tag/post-covid-syndrome/) and the illness has been termed "long-COVID syndrome" (https://directorsblog.nih.gov/2021/01/19/trying-to-makesense-of-long-covid-syndrome/). In fact, the National Institutes of Health (NIH, USA) recently devoted a 2-day conference on the epidemiology and pathophysiology of this illness (https://www.niaid.nih.gov/news-events/ workshop-post-acute-sequelae-covid-19). Other names used for this illness include "chronic COVID syndrome," "post-COVID syndrome," or "long haulers COVID syndrome." 21 In addition to the severe respiratory and inflammatory problems discussed above, infection with SARS-CoV-2 can also contribute to neurological 22-25 and mental 26-30 disorders. For this reason, NIH held an 1-day workshop on the effect of COVID-19 on the central nervous system (CNS) (https://www.ncbi.nlm.nih.gov/ search/research-news/11277/) and recently launched a database to track neurological symptoms associated with COVID-19 (https://www.nih.gov/news-events/ news-releases/nih-launches-database-track-neurologicalsymptoms-associated-covid-19). The importance of the effects of COVID-19 on the brain is highlighted by the blog recently posted by the NIH Director on this subject (https://directorsblog.nih.gov/2021/01/14/taking-a-closerlook-at-the-effects-of-covid-19-on-the-brain/). However, few scientific publication has so far discussed long-COVID syndrome (https://www.nytimes. com/2021/01/21/magazine/covid-aftereffects.html) such as the one that reported the presence of persistent fatigue apparently independent of the severity of the initial symptoms. 31 Symptoms experienced by long-COVID syndrome patients (Table 1 ) are very similar 32 to those present in patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), 33,34 mast cell activation syndrome (MCAS), 35, 36 or systemic mastocytosis (SM) 37 in whom the unique tissue immune cells, mast cells, are stimulated by environmental, pathogenic, and stress stimuli. Moreover, IL-6 has not only been implicated in COVID-19 8, 12 but was also elevated in ME/CFS 38 and SM. 39-41 To make matters worse, IL-6 promotes an increase in number of mast cells. 42 2 | CHEMOTHERAPY Patients undergoing chemotherapy are susceptible to infection with COVID- 19. 43 Moreover, more than 50% of patients on or following chemotherapy develop symptoms similar to those described above for long-COVID syndrome (Table 1) , especially cognitive dysfunction, 44-47 a condition that has been termed "chemofog" 48,49 or "chemobrain," 50-54 and has been associated with distinct neuroimaging findings. 55,56 A number of drugs have been implicated in "chemobrain" ( Table 2 ) most notably doxorubicin, 57-59 methotrexate, 60, 61 lenalidomide, 62 rituximab, 62 and trastuzamab. 63 There have been intense efforts to understand the biochemical 64 or cellular 44,65,66 mechanisms responsible for chemobrain. These have included disrupted neurogenesis, 67 aberrant myelination, 6869 interference with prefrontal activity, 70 but most importantly neuroinflammation 66 with cytokine dysregulation. 69, 71 T A B L E 1 Symptoms present in long-COVID syndrome • Inability to find the right words The symptoms listed, especially those bolded, are experienced, by many long-COVID syndrome patients and also patients undergoing or after having been administered chemotherapy. Microglia have important functions in the CNS, 72 especially with respect to neuroinflammation [72] [73] [74] and neurodegenerative [75] [76] [77] diseases. Microglia express Toll-like receptors (TLRs), 78 activated by damage-associated molecular patterns (DAMPs) and were recently implicated in COVID-19. 79,80 COVID-19 can also affect the hypothalamic-pituitary-adrenal (HPA) axis, 81 which is typically activated by stress and can further affect the emotional state of individuals affected by COVID-19. 82, 83 Microglia also express receptors for corticotropinreleasing hormone (CRH) 84 and could be further activated by stress, especially associated with COVID-19. 85 Microglia interact with the unique immune cells, mast cells, in the brain 86 leading to their activation 87 and neuroinflammation. 88 Activation of mast cells 89, 90 and microglia 91 in the hypothalamus 33 could lead to cognitive dysfunction 92 commonly also seen in patients with MCAS 93,94 ( Figure 1 ). Psychological stress has proinflammatory effects 82,95 via stimulation of mast cells, 83 especially by CRH 96 leading to increased vascular permeability. 83 This process also leads to disruption of the blood-brain barrier (BBB), 97,98 via release of IL-6 99 and CRH, 100 further exacerbating brain inflammation by permitting the entry into the brain of more viral particles, cytokines, or other toxic substances (Table 1) . A recent NIH study reported blood vessel damage and inflammation, but no infection, in brains of patients with COVID-19. 101 (https://www.nih.gov/news-events/news-releases/ nih-study-uncovers-blood-vessel-damage-inflammation- Note: The drugs listed, especially those bolded, have been reported to induce "chemofog" or "chemobrain". F I G U R E 1 Diagrammatic representation of how SARS-CoV-2 could stimulate mast cells and microglia in the hypothalamus, inhibited by luteolin. SARS-CoV-2 could enter the brain via the olfactory nerve tract reaching the hypothalamus where it could activate brain mast cells and microglia to release pro-inflammatory molecules, thus contributing to brain inflammation and brain fog. The effect of SARS-CoV-2 could be exaggerated by chemotherapy, as well as cytokines and mtDNA, or neuropeptides released under stress (thunderbolt). These processed could contribute to the pathogenesis and symptoms of long-COVID syndrome and "chomobrain" and could be prevented by the flavonoid luteolin covid-19-patients-brains-noinfection#::text=In%20an% 20in%2Ddepth%20study,shortly%20after%20contracting% 20the%20disease.) These findings may explain the recent comprehensive reports of significantly increased neurologic 102 and psychiatric 103 disorders in COVID-19 patients, as well as in long-COVID syndrome patients. 104 Mast cells are ubiquitous in the body 37 and are critical for allergic diseases, 105 but also inflammation. 106 Mast cells are also present in the brain, especially in the median eminence of the hypothalamus, where they are located perivascularly close to nerve endings positive for CRH. 107 Mast cells are also triggered by viruses 108 including SARS-CoV-2. 109,110 A recent publication using normal oral cavity mucosa reported no gene expression of the SARS-CoV-2 receptor, angiotensin converting enzyme 2 (ACE2) in mast cells. 111 However, mast cells are "plastic" and their surface receptors can be induced by a variety of conditions. For instance, we reported that the neuropeptides neurotensin 112 and substance P (SP) 113 can induce CRHR-1. Moreover, SP can induce the ST2 receptor for IL-33. 114 In fact, ACE2 gene expression was recently shown to be induced by interferon, 115 and mast cells can elicit strong pro-inflammatory and type I interferon responses in response to viruses, 116 implying an autocrine action on ACE2 expression. Of course, it remains to be seen to what extent pulmonary and/or brain mast cells from deceased COVID-19 patients express ACE2. Following stimulation, mast cells release proinflammatory mediators 117 such as histamine, tryptase, chemokines (e.g., CCL2, CCXL8) 118 and cytokines (IL-6, 119 IL-1β , 120 and tumor necrosis factor [TNF] 114 ), especially when primed by IL-33. 121, 122 Histamine can stimulate macrophages to release IL-1, 123 which stimulates mast cells to release IL-6. 119 Mast cells can also secrete mitochondrial DNA (mtDNA), 124 which was recently reported to be increased in the serum of COVID-19 patients and correlated with disease severity. 125 Extracellular mtDNA serves as an alarmin and stimulates pro-inflammatory mediator secretion from immune cells. 126, 127 Moreover, mast cells synthesize and release platelet activating factor (PAF), which has been implicated in the inflammation 128 and microthromboses 129 characterizing COVID-19. Unfortunately, there are no clinically effective interventions for long-COVID syndrome 1,130 or brain fog associated with either chemobrain, ME/CFS, 131 or MCAS. 36 It is also hard to decide whether it would be best to stimulate or suppress the immune system, 132,133 since antibody production and T cells appear to be protective, while proinflammatory cytokines are destructive. 1, 134, 135 A reasonable approach especially for brain fog associated with long-COVID syndrome, ME/CFS, MCAS, and chemotherapy-induced "chemobrain" would be inhibition of mast cell-associated neuroinflammation. Even though inhibition of mast cells could be beneficial in COVID-19 or long-COVID syndrome, 38 there are no effective mast cell inhibitors. 136 Instead, mast cells could be inhibited with the structurally related natural flavonoids luteolin and quercetin, [137] [138] [139] [140] [141] which are readily available and are generally considered safe 142-146 ( Figure 1 ). Both flavonoids have broad anti-viral properties, inhibit entry of the virus into host cells, 108, 147, 148 inhibit neuroinflammation, 149 and reduce cognitive decline. 150 Furthermore, luteolin better penetrates into the brain, inhibits both microglia 151, 152 and mast cells, 153, 154 and has been reported to reduce neuroinflammation 145, 155, 156 and cognitive dysfunction, 157, 158 including Alzheimer's disease in humans 159, 160 and in animal models. 161 Luteolin and quercetin are difficult to absorb after oral administration, 162 but their pharmacokinetics are greatly improved in liposomal preparations using olive pomace oil. 163 In fact, a luteolin formulation in olive pomace oil (NeuroProtek ® ) has been used effectively for improving autism spectrum disorder, 144, 164 while another one (BrainGain ® ) reduced brain fog. 157 These liposomal formulations not only improve oral absorption and bioavailability but also provide the additional neuroprotective [165] [166] [167] [168] [169] [170] and anti-inflammatory 171,172 actions of T A B L E 3 Important facts and outstanding issues concerning long-COVID syndrome • Long-COVID syndrome is a serious concern • Symptoms of long-COVID syndrome are similar to those present in ME/CFS, MCAS and during or after chemotherapy • The most vexing symptoms are chronic physical and mental fatigue (brain fog) • The mechanism underlying these symptoms is presently not known olive pomace oil polyphenols, as well as the increase in memory provided by the olive hydroxytyrosol 169, 173 present in BrainGain ® . However, one should be aware of the fact that luteolin is now present in numerous dietary supplements with misleading names (e.g., "luteolin complex") and wide variations in the source, content, and purity (often not disclosed at all) of luteolin. 163 The number of COVID-19 cases may turn out to be fewer and the associated burden to the health system more by the long-COVID syndrome. 174 Obviously, there are many outstanding issues to be investigated (Table 3 ). In the meantime, the brain fog associated with long-COVID syndrome and use of chemotherapy may be prevented/ reduced with appropriate luteolin formulations. AUTHOR CONTRIBUTIONS Theoharis C. Theoharides conceived the concept, critically reviewed the literature and wrote the manuscript. Christos Cholevas and Konstantinos Polyzoidis assisted with the review of the literature. Theoharis C. Theoharides is the Scientific Director of and shareholder in Algonot, LLC (Sarasota, FL), which develops and markets flavonoid-containing dietary supplements. He is also the recipient of US Patent No. 8,268,365, "Anti-inflammatory compositions for treating brain inflammation." The other authors declare no conflict of interest. The pathogenesis and treatment of the 'cytokine Storm' in COVID-19 Clinical and immunological features of severe and moderate coronavirus disease 2019 Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies Complex immune dysregulation in COVID-19 patients with severe respiratory failure Cytokine storm in COVID-19: the current evidence and treatment strategies COVID-19 and the immune system The COVID-19 cytokine storm; what we know so far Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19 Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19 The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy Childhood multisystem inflammatory syndrome -a new challenge in the pandemic Multisystem inflammatory syndrome in U.S. children and adolescents Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children COVID-19 and multisystem inflammatory syndrome in children and adolescents The immunology of multisystem inflammatory syndrome in children with COVID-19 Autoimmune and inflammatory diseases following COVID-19 Highways to hell: mechanism-based management of cytokine storm syndromes Chemobrain: a systematic review of structural and functional neuroimaging studies Opening up the window into "chemobrain": a neuroimaging review Doxorubicin chemotherapy-induced "chemobrain": meta-analysis Chemotherapy and cognition: comprehensive review on doxorubicininduced chemobrain Doxorubicin and cisplatin induced cognitive impairment: the possible mechanisms and interventions Methotrexate chemotherapy induces persistent tri-glial dysregulation that underlies chemotherapyrelated cognitive impairment Mast cell degranulation activates a pain pathway underlying migraine headache Similar neurocognitive patterns in patients treated with lenalidomide: chemobrain effect? Trastuzumab induced chemobrain, atorvastatin rescued chemobrain with enhanced anticancer effect and without hair loss-side effect Plausible biochemical mechanisms of chemotherapy-induced cognitive impairment ("chemobrain"), a condition that significantly impairs the quality of life of many cancer survivors Emerging mechanistic underpinnings and therapeutic targets for chemotherapy-related cognitive impairment Cellular mechanisms and treatments for chemobrain: insight from aging and neurodegenerative diseases Impaired cognitive function and hippocampal neurogenesis following cancer chemotherapy Aberrant adaptive myelination in 'chemobrain Chemobrain: a critical review and causal hypothesis of link between cytokines and epigenetic reprogramming associated with chemotherapy Cancer 'survivor-care': II. Disruption of prefrontal brain activation top-down control of working memory capacity as possible mechanism for chemo-fog/brain (chemotherapy-associated cognitive impairment) Dysregulation of cytokine mediated chemotherapy induced cognitive impairment Microglia function in the central nervous system during health and neurodegeneration Microgliamediated neuroinflammation in neurodegenerative diseases Microglia in central nervous system inflammation and multiple sclerosis pathology Microglia in neurodegenerative disease How neuroinflammation contributes to neurodegeneration Microglia in neurodegeneration TLR signaling tailors innate immune responses in human microglia and astrocytes Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and glial cells: insights and perspectives Severe acute respiratory syndrome coronavirus 2 impact on the central nervous system: are astrocytes and microglia main players or merely bystanders? Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the neuroendocrine stress axis Stress, inflammation, and autoimmunity: the 3 modern Erinyes Effect of psychological stress on mast cells Functional expression of corticotropin-releasing hormone (CRH) receptor 1 in cultured rat microglia COVID-19, mast cells, cytokine storm, psychological stress, and neuroinflammation. Neuroscientist Mast cells in neuroinflammation and brain disorders Induction of microglial activation by mediators released from mast cells Neuroinflammation, mast cells, and glia: dangerous liaisons The role of mast cells in Alzheimer's disease Mast cells in stress, pain, blood-brain barrier, neuroinflammation and Alzheimer's disease Microglia in Alzheimer's disease Activated brain mast cells contribute to postoperative cognitive dysfunction by evoking microglia activation and neuronal apoptosis Evidence for cognitive impairment in mastocytosis: prevalence, features and correlations to depression Mast cell activation disease: an underappreciated cause of neurologic and psychiatric symptoms and diseases Effect of stress on neuroimmune processes Mast cells as targets of corticotropinreleasing factor and related peptides Corticotropin-releasing hormone and the blood-brain-barrier Blood-brain barrier and intestinal epithelial barrier alterations in autism spectrum disorders Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans Corticotropinreleasing hormone and its structurally related urocortin are synthesized and secreted by human mast cells Microvascular injury in the brains of patients with Covid-19 Central nervous system manifestations in COVID-19 patients: a systematic review and meta-analysis Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA Deleterious outcomes in long-hauler COVID-19: the effects of SARS-CoV-2 on the CNS in chronic COVID syndrome Mast cells signal their importance in health and disease The development of allergic inflammation Morphological and functional demonstration of rat dura mast cell-neuron interactions in vitro and in vivo Mast cell responses to viruses and pathogen products Potential association of mast cells with COVID-19 Mast cells in alveolar septa of COVID-19 patients: a pathogenic pathway that may link interstitial edema to Immunothrombosis High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa Neurotensin and CRH interactions augment human mast cell activation Substance P (SP) induces expression of functional corticotropin-releasing hormone receptor-1 (CRHR-1) in human mast cells SP and IL-33 together markedly enhance TNF synthesis and secretion from human mast cells mediated by the interaction of their receptors SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial Cells and is detected in specific cell subsets across tissues Mast cells elicit proinflammatory but not type I interferon responses upon activation of TLRs by bacteria Mast cells as sources of cytokines, chemokines, and growth factors IL-33 stimulates human mast cell release of CCL5 and CCL2 via MAPK and NF-kappaB, inhibited by methoxyluteolin IL-1 induces vesicular secretion of IL-6 without degranulation from human mast cells Substance P and IL-33 administered together stimulate a marked secretion of IL-1beta from human mast cells, inhibited by methoxyluteolin The role of IL-33 and mast cells in allergy and inflammation Effect of IL-33 on de novo synthesized mediators from human mast cells Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19 Stimulated human mast cells secrete mitochondrial components that have autocrine and paracrine inflammatory actions Circulating mitochondrial DNA is an early indicator of severe illness and mortality from COVID-19 Endogenously oxidized mitochondrial DNA induces in vivo and in vitro inflammatory responses Mitochondrial DAMPs increase endothelial permeability through neutrophil dependent and independent pathways COVID-19, microthromboses, inflammation and platelet activating factor Coronavirus 2019, microthromboses, and platelet activating factor Weathering the cytokine storm in COVID-19: therapeutic implications Pharmaceutical interventions in chronic fatigue syndrome: a literature-based commentary Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions SARS-CoV-2, which induces COVID-19, causes Kawasaki-like disease in children: role of pro-inflammatory and anti-inflammatory cytokines Immune cells in term and preterm labor Dexamethasone for COVID-19? not so fast COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells Anti-oxidant, antiinflammatory and anti-allergic activities of luteolin The roles of flavonoles/ flavonoids in neurodegeneration and neuroinflammation Flavonoids and the CNS Flavonoids as cytokine modulators: a possible therapy for inflammation-related diseases A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties Safety of quercetin for clinical application (review) An open-label pilot study of a formulation containing the antiinflammatory flavonoid luteolin and its effects on behavior in children with autism spectrum disorders Brain inflammation, neuropsychiatric disorders, and immunoendocrine effects of luteolin Safety aspects of the use of quercetin as a dietary supplement Roles of flavonoids against coronavirus infection A role for quercetin in coronavirus disease 2019 (COVID-19) The roles of flavonols/flavonoids in neurodegeneration and neuroinflammation Polyphenols as an effective therapeutic intervention against cognitive decline during normal and pathological brain aging Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1 Neurotensin stimulates sortilin and mTOR in human microglia inhibitable by methoxyluteolin, a potential therapeutic target for autism The novel flavone tetramethoxyluteolin is a potent inhibitor of human mast cells Methoxyluteolin inhibits neuropeptide-stimulated proinflammatory mediator release via mTOR activation from human mast cells The flavone Luteolin improves central nervous system disorders by different mechanisms: a review Neuroprotective effects of flavone luteolin in neuroinflammation and neurotrauma Brain "fog," inflammation and obesity: key aspects of 2 neuropsychiatric disorders improved by luteolin Flavonoid-mediated presenilin-1 phosphorylation reduces Alzheimer's disease beta-amyloid production Luteolin as a potential preventive and therapeutic candidate for Alzheimer's disease Neuroinflammation in Alzheimer's disease and beneficial action of luteolin Ameliorating effect of luteolin on memory impairment in an Alzheimer's disease model Protective role of luteolin against cognitive dysfunction induced by chronic cerebral hypoperfusion in rats Luteolin supplements: all that glitters is not gold Children with autism Spectrum disorders, who improved with a luteolin containing dietary formulation, show reduced serum levels of TNF and IL-6 Phytochemistry: ibuprofen-like activity in extra-virgin olive oil Bioactivity of olive oil phenols in neuroprotection Olive polyphenols: new promising agents to combat aging-associated neurodegeneration Olive biophenols reduces Alzheimer's pathology in SH-SY5Y cells and APPswe mice Hydroxytyrosol, the major phenolic compound of olive oil, as an acute therapeutic strategy after ischemic stroke Olive oil phenols and neuroprotection Modulation of cytokine secretion by pentacyclic triterpenes from olive pomace oil in human mononuclear cells Phenolic compounds characteristic of the Mediterranean diet in mitigating microglia-mediated neuroinflammation Hydroxytyrosol: a natural compound with promising pharmacological activities Post-COVID-19 spending Long-COVID syndrome-associated brain fog and chemofog: Luteolin to the rescue